Pharmacovigilance Market Report
RA00466
Pharmacovigilance Market, by Service Provider (In-House, Contract Outsourcing), Clinical Trial Phase (Preclinical, Phase I, Phase II, Phase III, Phase IV): Global Opportunity Analysis and Industry Forecast, 2020-2027
The global pharmacovigilance market is estimated to surpass $10,822.4 million by 2027, exhibiting a CAGR of 10.8% from 2020 to 2027.
The report provides all-inclusive analysis of global pharmacovigilance market with comprehensive study of the various facets of the market including market dynamics, major segments and regions, top leading players, and competitive landscape.
The report emphasizes current market scenario and future trends of the global pharmacovigilance market which gleaned from the impact of various market dynamics such as drivers, challenges & restraints, lucrative opportunities. The report also highlights the key forces that are shaping the market. Besides, the report provides Porter’s five forces analysis which precisely underlines the impact of key forces on the global pharmacovigilance market.
In addition, the report provides market size and forecast scrutinizing global pharmacovigilance market through different segments. The report highlights the geographical market analysis of these segments and each segment is thoroughly studied at regional as well as country level to get clearer picture of the global pharmacovigilance market. In the report, the global pharmacovigilance market is divided into four major regions including North America, Europe, Asia-Pacific, and LAMEA. These regions are further divided into major countries to cover pharmacovigilance market landscape in respective regions.
Furthermore, competitive scenario of the global pharmacovigilance market is covered in the report. Major players functioning in the global pharmacovigilance market are also studied to understand their position and competitive strengths in the industry. The major company profiles covered in the report include various company’s datum such as brief overview, recent financials, main executives, adoption of key growth strategies, novel advancements or initiatives to sustain and expand their position in the global pharmacovigilance market, and others.
Research Methodology
Research Dive offers its clients extensive research and analysis gleaned from wide variety of factual inputs that largely includes interview with participants of the industry, reliable data & statistics, and regional intelligence. The in-house experts of the industry play a crucial role in designing analytic tools and models, tailor-made to the requests of an industry segment. The data and statistics are sterilized with these analytical tools and models, which enhances the accuracy of our advice and recommendations.
This research report is delivered by Research Dive by conducting long hours of discussions and interviews, with a broad range of stakeholders, which includes upstream and downstream participants. Our analysts have performed a mix of primary and secondary research for the market estimations and forecasts. A number of product type literatures, industry releases, annual reports, and other related documents of major participants of the industry have been reviewed, to better understand the global pharmacovigilance market scenario. The initial phase of our in-depth study, where we perform wide-range data mining, referring to proficient & verified data sources such as independent studies, medical journals, technical journals, releases by trade association, materials published by government & regulatory authorities, and other.
KEY MARKET BENEFITS
- This report is a compilation of detailed study, information, valid inputs from industry experts & industry participants across the value chain, and quantitative & qualitative assessment by analysts of the industry.
- The report provides a comprehensive analysis along with the current trends of market during the forecast period from 2019 to 2027 to identify & comprehend the prevailing opportunities and the strategic assessment of the global pharmacovigilance market growth.
- The report studies the market from 2019 to 2027 and maps the qualitative impact of several industry factors on market segments as well as geographies.
- The report provides market estimations and size which is based on in-depth analysis of recent & key developments in the pharmacovigilance market.
- The development strategies implemented by the key industry players are conscripted in the report to understand the competitive scenario of the global pharmacovigilance market.
KEY MARKET SEGMENTS
The market has been studied based on the following segments:
- Service Provider: In-House, Contract Outsourcing
- Clinical Trial Phase: Preclinical, Phase I, Phase II, Phase III, Phase IV
Region:
The global pharmacovigilance market is divided into North America, Europe, Asia Pacific, and LAMEA.
The above-mentioned regions are further dived in countries as follows:
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Argentina
- Saudi Arabia
- South Africa
- UAE
- Rest of LAMEA
KEY MARKET PLAYERS
The report covers the major players operating in the global pharmacovigilance market that focus on advancements & innovations and geographical expansion of product portfolios to obtain a competitive edge in the market space. The major players enlisted in the report include InVentiv Health Clinical, Clinquest Group, IBM Corporation, Infosys, …., and others.
The report summarizes various aspects of all these key players that include as follows:
1. Accenture
2. Boehringer Ingelheim
3. Bristol-Myers Squibb
4. Clinquest Group
5. Cognizant
6. Ecron Acunova
7. F. Hoffmann-La Roche
8. GlaxoSmithKline
9. HCL Technologies
10. IBM Corporation
11. ICON plc
12. iGATE Corporation
13. Infosys
14. InVentiv Health Clinical
15. Ipca Laboratories
-
1. RESEARCH METHODOLOGY
1.1. Desk Research
1.2. Real time insights and validation
1.3. Forecast model
1.4. Assumptions and forecast parameters
1.5. Market size estimation
1.5.1. Top-down approach
1.5.2. Bottom-up approach
-
2. REPORT SCOPE
2.1. Market definition
2.2. Key objectives of the study
2.3. Report overview
2.4. Market segmentation
2.5. Overview of the impact of COVID-19 on Global Pharmacovigilance Market
-
3. EXECUTIVE SUMMARY
-
4. MARKET OVERVIEW
4.1. Introduction
4.2. Growth impact forces
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Market value chain analysis
4.3.1. List of raw material suppliers
4.3.2. List of manufacturers
4.3.3. List of distributors
4.4. Innovation & sustainability matrices
4.4.1. Technology matrix
4.4.2. Regulatory matrix
4.5. Porter’s five forces analysis
4.5.1. Bargaining power of suppliers
4.5.2. Bargaining power of consumers
4.5.3. Threat of substitutes
4.5.4. Threat of new entrants
4.5.5. Competitive rivalry intensity
4.6. PESTLE analysis
4.6.1. Political
4.6.2. Economical
4.6.3. Social
4.6.4. Technological
4.6.5. Environmental
4.7. Impact of COVID-19 on Pharmacovigilance Market
4.7.1. Pre-covid market scenario
4.7.2. Post-covid market scenario
-
5. Pharmacovigilance Market, By Service Provider
5.1. Overview
5.2 In-House
5.2.1 Definition, key trends, growth factors, and opportunities
5.2.2 Market size analysis, by region, 2020-2027
5.2.3 Market share analysis, by country, 2020-2027
5.3 Contract Outsourcing
5.3.1 Definition, key trends, growth factors, and opportunities
5.3.2 Market size analysis, by region, 2020-2027
5.3.3 Market share analysis, by country, 2020-2027
5.4 Research Dive Exclusive Insights
5.4.1 Market attractiveness
5.4.2 Competition heatmap
-
6. Pharmacovigilance Market, By Clinical Trial Phase
6.1. Overview
6.2 Preclinical
6.2.1 Definition, key trends, growth factors, and opportunities
6.2.2 Market size analysis, by region, 2020-2027
6.2.3 Market share analysis, by country, 2020-2027
6.3 Phase I
6.3.1 Definition, key trends, growth factors, and opportunities
6.3.2 Market size analysis, by region, 2020-2027
6.3.3 Market share analysis, by country, 2020-2027
6.4 Phase II
6.4.1 Definition, key trends, growth factors, and opportunities
6.4.2 Market size analysis, by region, 2020-2027
6.4.3 Market share analysis, by country, 2020-2027
6.5 Phase III
6.5.1 Definition, key trends, growth factors, and opportunities
6.5.2 Market size analysis, by region, 2020-2027
6.5.3 Market share analysis, by country, 2020-2027
6.6 Phase IV
6.6.1 Definition, key trends, growth factors, and opportunities
6.6.2 Market size analysis, by region, 2020-2027
6.6.3 Market share analysis, by country, 2020-2027
6.7 Research Dive Exclusive Insights
6.7.1 Market attractiveness
6.7.2 Competition heatmap
7. Pharmacovigilance Market, By Region
7.1 North America
7.1.1 U.S
7.1.1.1 Market size analysis, By Service Provider, 2020-2027
7.1.1.2 Market size analysis, By Clinical Trial Phase, 2020-2027
7.1.2 Canada
7.1.2.1 Market size analysis, By Service Provider, 2020-2027
7.1.2.2 Market size analysis, By Clinical Trial Phase, 2020-2027
7.1.3 Mexico
7.1.3.1 Market size analysis, By Service Provider, 2020-2027
7.1.3.2 Market size analysis, By Clinical Trial Phase, 2020-2027
7.1.4 Research Dive Exclusive Insights
7.1.4.1 Market attractiveness
7.1.4.2 Competition heatmap
7.2 Europe
7.2.1 Germany
7.2.1.1 Market size analysis, By Service Provider, 2020-2027
7.2.1.2 Market size analysis, By Clinical Trial Phase, 2020-2027
7.2.2 UK
7.2.2.1 Market size analysis, By Service Provider, 2020-2027
7.2.2.2 Market size analysis, By Clinical Trial Phase, 2020-2027
7.2.3 France
7.2.3.1 Market size analysis, By Service Provider, 2020-2027
7.2.3.2 Market size analysis, By Clinical Trial Phase, 2020-2027
7.2.4 Spain
7.2.4.1 Market size analysis, By Service Provider, 2020-2027
7.2.4.2 Market size analysis, By Clinical Trial Phase, 2020-2027
7.2.5 Italy
7.2.5.1 Market size analysis, By Service Provider, 2020-2027
7.2.5.2 Market size analysis, By Clinical Trial Phase, 2020-2027
7.2.6 Rest of Europe
7.2.6.1 Market size analysis, By Service Provider, 2020-2027
7.2.6.2 Market size analysis, By Clinical Trial Phase, 2020-2027
7.2.7 Research Dive Exclusive Insights
7.2.7.1 Market attractiveness
7.2.7.2 Competition heatmap
7.3 Asia-Pacific
7.3.1 China
7.3.1.1 Market size analysis, By Service Provider, 2020-2027
7.3.1.2 Market size analysis, By Clinical Trial Phase, 2020-2027
7.3.2 Japan
7.3.2.1 Market size analysis, By Service Provider, 2020-2027
7.3.2.2 Market size analysis, By Clinical Trial Phase, 2020-2027
7.3.3 India
7.3.3.1 Market size analysis, By Service Provider, 2020-2027
7.3.3.2 Market size analysis, By Clinical Trial Phase, 2020-2027
7.3.4 Australia
7.3.4.1 Market size analysis, By Service Provider, 2020-2027
7.3.4.2 Market size analysis, By Clinical Trial Phase, 2020-2027
7.3.5 South Korea
7.3.5.1 Market size analysis, By Service Provider, 2020-2027
7.3.5.2 Market size analysis, By Clinical Trial Phase, 2020-2027
7.3.6 Rest of Asia-Pacific
7.3.6.1 Market size analysis, By Service Provider, 2020-2027
7.3.6.2 Market size analysis, By Clinical Trial Phase, 2020-2027
7.3.7 Research Dive Exclusive Insights
7.3.7.1 Market attractiveness
7.3.7.2 Competition heatmap
7.4 LAMEA
7.4.1 Brazil
7.4.1.1 Market size analysis, By Service Provider, 2020-2027
7.4.1.2 Market size analysis, By Clinical Trial Phase, 2020-2027
7.4.2 Saudi Arabia
7.4.2.1 Market size analysis, By Service Provider, 2020-2027
7.4.2.2 Market size analysis, By Clinical Trial Phase, 2020-2027
7.4.3 UAE
7.4.3.1 Market size analysis, By Service Provider, 2020-2027
7.4.3.2 Market size analysis, By Clinical Trial Phase, 2020-2027
7.4.4 South Africa
7.4.4.1 Market size analysis, By Service Provider, 2020-2027
7.4.4.2 Market size analysis, By Clinical Trial Phase, 2020-2027
7.4.5 Rest of LAMEA
7.4.5.1 Market size analysis, By Service Provider, 2020-2027
7.4.5.2 Market size analysis, By Clinical Trial Phase, 2020-2027
7.4.6 Research Dive Exclusive Insights
7.4.6.1 Market attractiveness
7.4.6.2 Competition heatmap
8. Competitive Landscape
8.1 Top winning strategies, 2020-2027
8.1.1 By strategy
8.1.2 By year
8.2 Strategic overview
8.3 Market share analysis, 2020-2027
9. Company Profiles
9.1 Accenture
9.1.1 Overview
9.1.2 Business segments
9.1.3 Product portfolio
9.1.4 Financial performance
9.1.5 Recent developments
9.1.6 SWOT analysis
9.2 Boehringer Ingelheim
9.2.1 Overview
9.2.2 Business segments
9.2.3 Product portfolio
9.2.4 Financial performance
9.2.5 Recent developments
9.2.6 SWOT analysis
9.3 Bristol-Myers Squibb
9.3.1 Overview
9.3.2 Business segments
9.3.3 Product portfolio
9.3.4 Financial performance
9.3.5 Recent developments
9.3.6 SWOT analysis
9.4 Clinquest Group
9.4.1 Overview
9.4.2 Business segments
9.4.3 Product portfolio
9.4.4 Financial performance
9.4.5 Recent developments
9.4.6 SWOT analysis
9.5 Cognizant
9.5.1 Overview
9.5.2 Business segments
9.5.3 Product portfolio
9.5.4 Financial performance
9.5.5 Recent developments
9.5.6 SWOT analysis
9.6 Ecron Acunova
9.6.1 Overview
9.6.2 Business segments
9.6.3 Product portfolio
9.6.4 Financial performance
9.6.5 Recent developments
9.6.6 SWOT analysis
9.7 F. Hoffmann-La Roche
9.7.1 Overview
9.7.2 Business segments
9.7.3 Product portfolio
9.7.4 Financial performance
9.7.5 Recent developments
9.7.6 SWOT analysis
9.8 GlaxoSmithKline
9.8.1 Overview
9.8.2 Business segments
9.8.3 Product portfolio
9.8.4 Financial performance
9.8.5 Recent developments
9.8.6 SWOT analysis
9.9 HCL Technologies
9.9.1 Overview
9.9.2 Business segments
9.9.3 Product portfolio
9.9.4 Financial performance
9.9.5 Recent developments
9.9.6 SWOT analysis
9.10 IBM Corporation
9.10.1 Overview
9.10.2 Business segments
9.10.3 Product portfolio
9.10.4 Financial performance
9.10.5 Recent developments
9.10.6 SWOT analysis
9.11 ICON plc
9.11.1 Overview
9.11.2 Business segments
9.11.3 Product portfolio
9.11.4 Financial performance
9.11.5 Recent developments
9.11.6 SWOT analysis
9.12 iGATE Corporation
9.12.1 Overview
9.12.2 Business segments
9.12.3 Product portfolio
9.12.4 Financial performance
9.12.5 Recent developments
9.12.6 SWOT analysis
9.13 Infosys
9.13.1 Overview
9.13.2 Business segments
9.13.3 Product portfolio
9.13.4 Financial performance
9.13.5 Recent developments
9.13.6 SWOT analysis
9.14 InVentiv Health Clinical
9.14.1 Overview
9.14.2 Business segments
9.14.3 Product portfolio
9.14.4 Financial performance
9.14.5 Recent developments
9.14.6 SWOT analysis
9.15 Ipca Laboratories
9.15.1 Overview
9.15.2 Business segments
9.15.3 Product portfolio
9.15.4 Financial performance
9.15.5 Recent developments
9.15.6 SWOT analysis
Personalize this research
- Triangulate with your own data
- Request your format and definition
- Get a deeper dive on a specific application, geography, customer or competitor
- + 1-888-961-4454 Toll - Free
- support@researchdive.com
